Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 17/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4996395 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL4995168 | 0.89 | OPRD1 (0.80) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL4999933 | 0.88 | OPRD1 (0.79) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL14030464 | 0.85 | OPRD1 (0.74) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL4999928 | 0.85 | OPRD1 (0.73) | OPRD1OPRM1KCNH2RAB9AOPRK1 | |
| SCHEMBL4999897 | 0.83 | OPRD1 (0.71) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL5971267 | 0.83 | OPRD1 (0.71) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL4934238 | 0.83 | OPRD1 (0.70) | OPRD1OPRM1KCNH2RAB9AOPRK1 | |
| SCHEMBL6109347 | 0.82 | OPRD1 (0.85) | OPRD1OPRM1KCNH2OPRK1 | |
| SCHEMBL5000077 | 0.80 | OPRD1 (0.82) | OPRD1OPRM1KCNH2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262038-A1 | Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | claimed |
| EP-1706380-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-10-04 | — | — | EP | claimed |
| WO-2005066128-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-07-21 | — | — | WO | claimed |
| US-20080262038-A1 | Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262038-A1 | Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262038-A1 | Diarylmethylidene Piperidine Derivatives, Preparations Thereof and Uses Thereof | OPRM1, OPRD1, OPRL1 | OPRD1 2/4885OPRM1 1/4885KCNH2 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.